Bleeding complications of oral anticoagulant treatment

An inception-cohort, prospective collaborative study (ISCOAT)

Gualtiero Palareti, Nicoletta Leali, Sergio Coccheri, Mario Poggi, Cesare Manotti, Armando D'Angelo, Vittorio Pengo, Nicoletta Erba, Marco Moia, Nicola Ciavarella, Gianluigi Devoto, Mauro Berrettini, Serena Musolesi

Research output: Contribution to journalArticle

1219 Citations (Scopus)

Abstract

Background. Bleeding is the most serious complication of the use of oral anticoagulation in the prevention and treatment of thromoboembolic complications. We studied the frequency of bleeding complications in outpatients treated routinely in anticoagulation clinics. Methods. In a prospective cohort from thirty-four Italian anticoagulation clinics, 2745 consecutive patients were studied from the start of their oral anticoagulation (warfarin in 64%, acenocourmarol in the rest). The target anticoagulation-intensity was low (international normalised ratio [INR] ≤ 2.8) in 71% of the patients and high (> 2.8) in the remainder. We recorded demographic details and the main indication for treatment and, every 3-4 months, INR and outcome events. Such events included all complications (bleeding, thrombosis, other), although only bleeding events are reported here, and deaths. We divided bleeding into major and minor categories. Findings. 43% of the patients were women. Nearly three-fifths of the patients were aged 60-79; 8% were over 80. The main indication for treatment was venous thrombolism (33%), followed by non-ischaemic heart disease (17%). Mean follow-up was 267 days. Over 2011 patient-years of follow-up, 153 bleeding complications occurred (7.6 per 100 patient-years). 5 were fatal (all cerebral haemorrhages, 0.25 per 100 patient-years), 23 were major (1.1), and 125 were minor (6.2). The rate of events was similar between sexes, coumarin type, size of enrolling centre, and target INR. The rate was higher in older patients: 10.5 per 100 patient-years in those aged 70 or over, 6.0 in those aged under 70 (relative risk 1.75, 95% CI 1.29-2.39, p <0.001). The rate was also higher when the indication was peripheral and/or cerebrovascular disease than venous thromboembolism plus other indications (12.5 vs 6.0 per 100 patient-years) (1.80, 1.2-2.7, p <0.01), and during the first 90 days of treatment compared with later (11.0 vs 6.3, 1.75, 1.27-2.44, p <0.001). A fifth of the bleeding events occurred at low anticoagulation intensity (INR <2, rate 7.7 per 100 patient-years of follow-up). The rates were 4.8, 9.5, 40.5, and 200 at INRs 2.0-2.9, 3-4.4, 4.5-6.9, and over 7, respectively (relative risks for INR > 4.5, 7.91, 5.44-11.5, p <0.0001). Interpretation. We saw fewer bleeding events than those recorded in other observational and experimental studies. Oral anticoagulation has become safer in recent years, especially if monitored in anticoagulation clinics. Caution is required in elderly patients and anticoagulation intensity should be closely monitored to reduce periods of overdosing.

Original languageEnglish
Pages (from-to)423-428
Number of pages6
JournalLancet
Volume348
Issue number9025
DOIs
Publication statusPublished - Aug 17 1996

Fingerprint

Anticoagulants
Prospective Studies
Hemorrhage
International Normalized Ratio
Therapeutics
Cerebral Hemorrhage
Warfarin
Observational Studies
Heart Diseases
Thrombosis
Outpatients
Demography

ASJC Scopus subject areas

  • Medicine(all)

Cite this

Bleeding complications of oral anticoagulant treatment : An inception-cohort, prospective collaborative study (ISCOAT). / Palareti, Gualtiero; Leali, Nicoletta; Coccheri, Sergio; Poggi, Mario; Manotti, Cesare; D'Angelo, Armando; Pengo, Vittorio; Erba, Nicoletta; Moia, Marco; Ciavarella, Nicola; Devoto, Gianluigi; Berrettini, Mauro; Musolesi, Serena.

In: Lancet, Vol. 348, No. 9025, 17.08.1996, p. 423-428.

Research output: Contribution to journalArticle

Palareti, G, Leali, N, Coccheri, S, Poggi, M, Manotti, C, D'Angelo, A, Pengo, V, Erba, N, Moia, M, Ciavarella, N, Devoto, G, Berrettini, M & Musolesi, S 1996, 'Bleeding complications of oral anticoagulant treatment: An inception-cohort, prospective collaborative study (ISCOAT)', Lancet, vol. 348, no. 9025, pp. 423-428. https://doi.org/10.1016/S0140-6736(96)01109-9
Palareti, Gualtiero ; Leali, Nicoletta ; Coccheri, Sergio ; Poggi, Mario ; Manotti, Cesare ; D'Angelo, Armando ; Pengo, Vittorio ; Erba, Nicoletta ; Moia, Marco ; Ciavarella, Nicola ; Devoto, Gianluigi ; Berrettini, Mauro ; Musolesi, Serena. / Bleeding complications of oral anticoagulant treatment : An inception-cohort, prospective collaborative study (ISCOAT). In: Lancet. 1996 ; Vol. 348, No. 9025. pp. 423-428.
@article{aa25fd3bb395469893867bd1e57d3dd5,
title = "Bleeding complications of oral anticoagulant treatment: An inception-cohort, prospective collaborative study (ISCOAT)",
abstract = "Background. Bleeding is the most serious complication of the use of oral anticoagulation in the prevention and treatment of thromoboembolic complications. We studied the frequency of bleeding complications in outpatients treated routinely in anticoagulation clinics. Methods. In a prospective cohort from thirty-four Italian anticoagulation clinics, 2745 consecutive patients were studied from the start of their oral anticoagulation (warfarin in 64{\%}, acenocourmarol in the rest). The target anticoagulation-intensity was low (international normalised ratio [INR] ≤ 2.8) in 71{\%} of the patients and high (> 2.8) in the remainder. We recorded demographic details and the main indication for treatment and, every 3-4 months, INR and outcome events. Such events included all complications (bleeding, thrombosis, other), although only bleeding events are reported here, and deaths. We divided bleeding into major and minor categories. Findings. 43{\%} of the patients were women. Nearly three-fifths of the patients were aged 60-79; 8{\%} were over 80. The main indication for treatment was venous thrombolism (33{\%}), followed by non-ischaemic heart disease (17{\%}). Mean follow-up was 267 days. Over 2011 patient-years of follow-up, 153 bleeding complications occurred (7.6 per 100 patient-years). 5 were fatal (all cerebral haemorrhages, 0.25 per 100 patient-years), 23 were major (1.1), and 125 were minor (6.2). The rate of events was similar between sexes, coumarin type, size of enrolling centre, and target INR. The rate was higher in older patients: 10.5 per 100 patient-years in those aged 70 or over, 6.0 in those aged under 70 (relative risk 1.75, 95{\%} CI 1.29-2.39, p <0.001). The rate was also higher when the indication was peripheral and/or cerebrovascular disease than venous thromboembolism plus other indications (12.5 vs 6.0 per 100 patient-years) (1.80, 1.2-2.7, p <0.01), and during the first 90 days of treatment compared with later (11.0 vs 6.3, 1.75, 1.27-2.44, p <0.001). A fifth of the bleeding events occurred at low anticoagulation intensity (INR <2, rate 7.7 per 100 patient-years of follow-up). The rates were 4.8, 9.5, 40.5, and 200 at INRs 2.0-2.9, 3-4.4, 4.5-6.9, and over 7, respectively (relative risks for INR > 4.5, 7.91, 5.44-11.5, p <0.0001). Interpretation. We saw fewer bleeding events than those recorded in other observational and experimental studies. Oral anticoagulation has become safer in recent years, especially if monitored in anticoagulation clinics. Caution is required in elderly patients and anticoagulation intensity should be closely monitored to reduce periods of overdosing.",
author = "Gualtiero Palareti and Nicoletta Leali and Sergio Coccheri and Mario Poggi and Cesare Manotti and Armando D'Angelo and Vittorio Pengo and Nicoletta Erba and Marco Moia and Nicola Ciavarella and Gianluigi Devoto and Mauro Berrettini and Serena Musolesi",
year = "1996",
month = "8",
day = "17",
doi = "10.1016/S0140-6736(96)01109-9",
language = "English",
volume = "348",
pages = "423--428",
journal = "The Lancet",
issn = "0140-6736",
publisher = "Lancet Publishing Group",
number = "9025",

}

TY - JOUR

T1 - Bleeding complications of oral anticoagulant treatment

T2 - An inception-cohort, prospective collaborative study (ISCOAT)

AU - Palareti, Gualtiero

AU - Leali, Nicoletta

AU - Coccheri, Sergio

AU - Poggi, Mario

AU - Manotti, Cesare

AU - D'Angelo, Armando

AU - Pengo, Vittorio

AU - Erba, Nicoletta

AU - Moia, Marco

AU - Ciavarella, Nicola

AU - Devoto, Gianluigi

AU - Berrettini, Mauro

AU - Musolesi, Serena

PY - 1996/8/17

Y1 - 1996/8/17

N2 - Background. Bleeding is the most serious complication of the use of oral anticoagulation in the prevention and treatment of thromoboembolic complications. We studied the frequency of bleeding complications in outpatients treated routinely in anticoagulation clinics. Methods. In a prospective cohort from thirty-four Italian anticoagulation clinics, 2745 consecutive patients were studied from the start of their oral anticoagulation (warfarin in 64%, acenocourmarol in the rest). The target anticoagulation-intensity was low (international normalised ratio [INR] ≤ 2.8) in 71% of the patients and high (> 2.8) in the remainder. We recorded demographic details and the main indication for treatment and, every 3-4 months, INR and outcome events. Such events included all complications (bleeding, thrombosis, other), although only bleeding events are reported here, and deaths. We divided bleeding into major and minor categories. Findings. 43% of the patients were women. Nearly three-fifths of the patients were aged 60-79; 8% were over 80. The main indication for treatment was venous thrombolism (33%), followed by non-ischaemic heart disease (17%). Mean follow-up was 267 days. Over 2011 patient-years of follow-up, 153 bleeding complications occurred (7.6 per 100 patient-years). 5 were fatal (all cerebral haemorrhages, 0.25 per 100 patient-years), 23 were major (1.1), and 125 were minor (6.2). The rate of events was similar between sexes, coumarin type, size of enrolling centre, and target INR. The rate was higher in older patients: 10.5 per 100 patient-years in those aged 70 or over, 6.0 in those aged under 70 (relative risk 1.75, 95% CI 1.29-2.39, p <0.001). The rate was also higher when the indication was peripheral and/or cerebrovascular disease than venous thromboembolism plus other indications (12.5 vs 6.0 per 100 patient-years) (1.80, 1.2-2.7, p <0.01), and during the first 90 days of treatment compared with later (11.0 vs 6.3, 1.75, 1.27-2.44, p <0.001). A fifth of the bleeding events occurred at low anticoagulation intensity (INR <2, rate 7.7 per 100 patient-years of follow-up). The rates were 4.8, 9.5, 40.5, and 200 at INRs 2.0-2.9, 3-4.4, 4.5-6.9, and over 7, respectively (relative risks for INR > 4.5, 7.91, 5.44-11.5, p <0.0001). Interpretation. We saw fewer bleeding events than those recorded in other observational and experimental studies. Oral anticoagulation has become safer in recent years, especially if monitored in anticoagulation clinics. Caution is required in elderly patients and anticoagulation intensity should be closely monitored to reduce periods of overdosing.

AB - Background. Bleeding is the most serious complication of the use of oral anticoagulation in the prevention and treatment of thromoboembolic complications. We studied the frequency of bleeding complications in outpatients treated routinely in anticoagulation clinics. Methods. In a prospective cohort from thirty-four Italian anticoagulation clinics, 2745 consecutive patients were studied from the start of their oral anticoagulation (warfarin in 64%, acenocourmarol in the rest). The target anticoagulation-intensity was low (international normalised ratio [INR] ≤ 2.8) in 71% of the patients and high (> 2.8) in the remainder. We recorded demographic details and the main indication for treatment and, every 3-4 months, INR and outcome events. Such events included all complications (bleeding, thrombosis, other), although only bleeding events are reported here, and deaths. We divided bleeding into major and minor categories. Findings. 43% of the patients were women. Nearly three-fifths of the patients were aged 60-79; 8% were over 80. The main indication for treatment was venous thrombolism (33%), followed by non-ischaemic heart disease (17%). Mean follow-up was 267 days. Over 2011 patient-years of follow-up, 153 bleeding complications occurred (7.6 per 100 patient-years). 5 were fatal (all cerebral haemorrhages, 0.25 per 100 patient-years), 23 were major (1.1), and 125 were minor (6.2). The rate of events was similar between sexes, coumarin type, size of enrolling centre, and target INR. The rate was higher in older patients: 10.5 per 100 patient-years in those aged 70 or over, 6.0 in those aged under 70 (relative risk 1.75, 95% CI 1.29-2.39, p <0.001). The rate was also higher when the indication was peripheral and/or cerebrovascular disease than venous thromboembolism plus other indications (12.5 vs 6.0 per 100 patient-years) (1.80, 1.2-2.7, p <0.01), and during the first 90 days of treatment compared with later (11.0 vs 6.3, 1.75, 1.27-2.44, p <0.001). A fifth of the bleeding events occurred at low anticoagulation intensity (INR <2, rate 7.7 per 100 patient-years of follow-up). The rates were 4.8, 9.5, 40.5, and 200 at INRs 2.0-2.9, 3-4.4, 4.5-6.9, and over 7, respectively (relative risks for INR > 4.5, 7.91, 5.44-11.5, p <0.0001). Interpretation. We saw fewer bleeding events than those recorded in other observational and experimental studies. Oral anticoagulation has become safer in recent years, especially if monitored in anticoagulation clinics. Caution is required in elderly patients and anticoagulation intensity should be closely monitored to reduce periods of overdosing.

UR - http://www.scopus.com/inward/record.url?scp=15844427401&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=15844427401&partnerID=8YFLogxK

U2 - 10.1016/S0140-6736(96)01109-9

DO - 10.1016/S0140-6736(96)01109-9

M3 - Article

VL - 348

SP - 423

EP - 428

JO - The Lancet

JF - The Lancet

SN - 0140-6736

IS - 9025

ER -